India plans incentives for diabetes, obesity drug makers

Original Article by Rishika Sadam | Reuters | 28 June 2024

India will incentivise local GLP-1 drug manufacturing by 2026, targeting diabetes and obesity treatments, as Novo Nordisk's patent expires.

India will incentivise local GLP-1 drug manufacturing by 2026, targeting diabetes and obesity treatments, as Novo Nordisk’s patent expires.

Subscription Required

You must be a subscriber to access all of this content.

View Subscriptions

Already a subscriber? Log in here